ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells

Area of Science:

• Molecular oncology
• Cancer cell signaling
• Prostate cancer research

Background:

• Prostate cancer remains a leading cause of cancer mortality in men.
• Aggressive forms, like castrate-resistant and metastatic prostate cancer, lack understood molecular drivers.
• ERBB2 and RAS oncogene pathways are frequently altered in metastatic prostate cancers.

Purpose of the Study:

• To define the role of the ERBB2/RAS pathway in prostate cancer metastasis.
• To evaluate the impact of ERBB2 or RAS overexpression on metastatic potential in prostate cancer cell lines with varying androgen sensitivities.

Main Methods:

• Transfection of human (DU145, LnCaP, PC3) and murine (Myc-CaP) prostate cancer cell lines with activated ERBB2 or H-RAS.
• Assessment of metastatic potential using wound healing, transwell motility, and transwell invasion assays.

Main Results:

• ERBB2 overexpression significantly increased metastatic potential in androgen-insensitive cell lines (PC3, DU145).
• ERBB2 overexpression did not affect metastatic potential in androgen-sensitive cell lines (LnCaP, Myc-CaP).
• H-RAS overexpression primarily increased cell motility in Myc-CaP cells (which overexpress c-MYC), but did not fully replicate ERBB2's metastatic effects.

Conclusions:

• ERBB2 collaborates with androgen signaling to drive prostate cancer metastasis.
• RAS, a downstream effector of ERBB2, does not fully phenocopy ERBB2's role in prostate cancer cell line metastasis.
• Understanding ERBB2's specific role in metastasis, particularly in conjunction with androgen signaling, is crucial for developing targeted therapies.